Our mission is to enable our clients to unearth novel insights that transform the landscape of life sciences and accelerate the discovery of new drugs and therapies, for the benefit of current and future generations.
At Asgard Sciences, we are driven by a relentless pursuit of scientific breakthroughs to redefine the boundaries of discovery.
Why Asgard
Every single person of Asgard believes that the true path of biological discovery is essential for curing diseases and improving the human condition. Our experiences have shown us that negotiating the path is difficult and unyielding, but when it is done right the outcome is profoundly good. We know that timely and useful research insights make or break therapeutic programs.
How We Work
Our starting point is to rigorously explore, define, and articulate our clients’ research objectives and then map the path of discovery to it We challenge our operating assumptions at every step along the way and we maintain endpoint focus throughout mid-course corrections.
What We Do
Asgard works with its clients around the world to make research plans with the best chances of success. We procure and integrate the best scientific services in order to deliver useful research endpoints. We manage all phases of the complex discovery workflows from sample accessioning and curation throughout myriad molecular biology analyses that ultimately form systems-level understanding. Our program management and insight delivery allow our clients to focus on the scientific questions that matter.
Meet The Leadership Team
With decades of experience working across different aspects of the R&D spectrum, the Asgard senior leadership team recognises the need to overcome siloed limitations and unleash the real potential for molecular biology applications to deliver truly impactful and reliable insights.
Managing Director
Dr. Colm Galligan, MB,MSc,MBA,FFPM,CDir
Dr. Colm Galligan is a clinician, biopharma veteran, health technology leader and entrepreneur. Throughout his career, as both a practicing clinician and a pharma executive, he delivered uniquely effective insights that drove strong collaborations in order to deliver the right medicines to the right patients at the right time. As a business leader, Dr. Galligan repeatedly integrated the perspectives of the complex healthcare ecosystem with the esoteric R&D machine that powers continual innovation in the sector.
Read more..He has worked across most therapeutic areas but has recently focused on groundbreaking advances in immunology and oncology, including novel modalities.
Also serves as Chief Medical Officer at RemedyBio. Previous roles include Medical Director at Novo Nordisk and Medical Director at Merck/MSD. Dr. Galligan has initiated, developed and delivered on many complex clinical & research programmes.
Dr. Galligan holds a Medical Degree from Trinity College Dublin, and Master of Business Administration from University College Dublin Smurfit School of Business, is a Fellow of the Faculty of Pharmaceutical Medicine Royal College of Physicians (UK) and a Chartered Director.
Chief Information Officer
Mike Lacey, MBA
Mr. Mike Lacey is a seasoned Information Technology leader and Chief Technical Architect with an extensive track record of building and managing technical teams to deliver strategically innovative IT solutions and services. As an expert in both distributed computing platforms and information security, he led the architecture development and implementation of large corporate IT systems from on-premise infrastructure to fully cloud-based systems.
Read more..Specializing in the integration of management objectives with differing international data protection laws. In addition to this, he has extensive commercial management and technology experience including software development and bioinformatics compute environments.
Previous roles include Vice President of Global IT Operations at Genuity Science and previously Vice President of Operations and IT at Genomics Medicine Ireland. Mr. Lacey has also been Managing Director of an Electronics and Engineering Design company and held Product and Technical Management roles in several major European companies.
Mr. Lacey holds a Master’s in Business Administration (MBA), Post Graduate Diploma in Management and a Higher National Diploma with Distinctions in Electrical and Electronics Engineering, along with qualifications in Project Management.
Senior Vice President, Operations
Dr. Jillian Dunleavy, PhD
Dr. Jillian Dunleavy is a senior operations leader with experience in genomics, clinical research and life sciences start-ups. Dr. Dunleavy is driven to use best possible technologies and R&D practices in order to positively impact the development of effective therapies and deliver meaningful healthcare. Her extensive life-sciences background ranges from discovering new disease genes to designing operational processes for multinational companies.
Read more..With broad experience in clinical research, business operations, project management, quality management , data protection and data management, Dr. Dunleavy takes a systems integration approach to successfully deliver business objectives.
In previous roles, she developed and led both process and project management, added structure to scaling companies, built company cohesiveness, and improved efficiency between cross-functional and cross-geography operations.
Previous roles include Senior Director of Business Operations and Director of Project Delivery at Genuity Science, Research Associate specialising in rare disorders, and Lecturer in Genomics.
Dr. Dunleavy holds a BSc Genetics Degree from University College Cork, a PhD in Medical Genetics from University College Dublin, and Qualifications in Project Management and Business Management.
Senior Vice President, Business Development
Dr. Jill Van Wart-Hood, PhD
Dr Jill Van Wart-Hood is a molecular biologist and pharmaceutical / biotech professional with two decades of domain-specific experience in oncology therapeutics development, immune-based diagnostics, and novel therapeutic target discovery. Her extensive life sciences experience ranges from small biotech companies to the largest multinational pharmaceutical corporations.
Read more..Dr. Van Wart-Hood led efforts within and between top-ten global pharma to develop novel therapeutics through both clinical development and FDA/EMEA regulatory approval.
In the field of novel diagnostics, she has led teams achieving US FDA clearance of targeted immune as well as biomarker focused novel diagnostics.
As a Business Development professional Dr. Van Wart-Hood has an extensive track record of international commercial collaborations between biotech and pharma.
Previous roles include Medical Director of Oncology (Teva), Sr Director BD (Adaptive Bio), VP Genomics Partnerships (Sequence Bio), and global medical lead Oncology (Daiichi Sankyo).
Dr. Van Wart-Hood holds a PhD in Molecular Biology from the University of Texas.
